Skip to content
ClinCalc Pro
Menu
Mood Stabiliser (Sodium Channel Blocker) — Bipolar Disorder

Carbamazepine (Psychiatric Use)

Brand names: Tegretol, Tegretol Retard (modified-release)

Carbamazepine is used in psychiatry as a mood stabiliser, principally for the prophylaxis of bipolar affective disorder in patients unresponsive to lithium, and in acute mania.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It stabilises hyperexcitable neuronal membranes mainly by blocking voltage-gated sodium channels, reducing repetitive neuronal firing and pathological neurotransmission.

Prescribing in practice

  • It is a potent inducer of hepatic enzymes and therefore reduces the effectiveness of many co-prescribed drugs, including hormonal contraceptives, so interaction checks are essential.
  • Warn patients about signs of blood, liver and skin disorders (including potentially life-threatening rashes such as Stevens-Johnson syndrome) and the increased serious-cutaneous-reaction risk associated with the HLA-B*1502 allele in relevant ancestries.
  • It is teratogenic and should be avoided in pregnancy and in women of childbearing potential not using effective contraception unless there is no safer alternative.

Monitoring

Monitor full blood count, liver function and, where indicated, plasma carbamazepine concentration, alongside review of mood and emergent rashes.

Counselling the patient

  • Seek urgent medical advice if you develop a fever, mouth ulcers, bruising, a rash or yellowing of the skin.
  • This drug can stop hormonal contraception working, so discuss reliable contraception.
  • Do not stop suddenly without medical advice.

Evidence & guidelines

Carbamazepine is recognised in NICE guidance as a mood-stabilising option in bipolar disorder; MHRA advice highlights teratogenicity and serious cutaneous reactions.

Reference: NICE CG185 (Bipolar Disorder); MHRA HLA-B*1502 Safety Update; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.